Abstract: Disclosed herein are methods for promoting weight loss in a subject by administering to the subject a composition comprising from about 2 mg to about 800 mg of paraxanthine. In certain aspects, paraxanthine is present in the composition in amount from about 20 mg to about 600 mg. In further aspects, paraxanthine is present in the composition in amount from about 50 mg to about 400 mg. According to certain embodiments, weight loss is promoted through inducing thermogenesis in the subject. In further embodiments, weight loss is promoted through enhancing lipolysis in the subject. According to certain implementations, administration of the composition to the subject decreases the respiratory quotient in the subject by at least about 10%.

Abstract: Disclosed herein are compositions and methods for attenuating stress-induced mental fatigue in subject in need thereof by administering to the subject a composition comprising from about 2 mg to about 800 mg of paraxanthine. In certain embodiments, paraxanthine is present in the composition in amount from about 20 mg to about 600 mg. In further embodiments, paraxanthine is present in the composition in amount from about 50 mg to about 400 mg. According to certain embodiments, fatigue attenuated by the instantly disclosed method is a result of physical stress on the subject. Physical stresses that may result in mental fatigue include, but are not limited to, periods of intense exercise.

Abstract: The present disclosure pertains to compositions and methods for the treatment and/or prevention of one or more of obesity, diabetes, metabolic syndrome, Alzheimer's disease, Chronic Fatigue Syndrome (CFS), aging, fibromyalgia, dyslipidemia, hypercholesterolemia, dyslipidemia, Parkinson's disease, migraines, Traumatic Brain Injury (TBI), Attention Deficit Disorder (ADD)/Attention Deficit Hyperactivity Disorder (ADHD), Cancer, Cardiovascular Disease (CVD)/Coronary Artery Disease (CAD), Chronic Pain, neuralgia, depression, amyotrophic lateral sclerosis (ALS), and epilepsy, Insufficient Cellular Energy (ICE) and mitochondrial dysfunction. The present disclosure also pertains to methods for increasing mental and/or physical performance levels and/or decreasing exertion during exercise in a subject by the administration of C5 ketones.

Abstract: The subject invention relates to a genetically modified microorganism comprising a (R)-3-hydroxybutyric acid pathway and being able of producing (R)-3-hydroxybutyric acid, and a method of preparing (R)-3-hydroxybutyric acid or a salt thereof using the genetically modified microorganism.

Abstract: The present disclosure pertains to compositions and methods for the treatment and/or prevention of one or more of obesity, diabetes, metabolic syndrome, Alzheimer's disease, Chronic Fatigue Syndrome (CFS), aging, fibromyalgia, dyslipidemia, hypercholesterolemia, dyslipidemia, Parkinson's disease, migraines, Traumatic Brain Injury (TBI), Attention Deficit Disorder (ADD)/Attention Deficit Hyperactivity Disorder (ADHD), Cancer, Cardiovascular Disease (CVD)/Coronary Artery Disease (CAD), Chronic Pain, neuralgia, depression, amyotrophic lateral sclerosis (ALS), and epilepsy, Insufficient Cellular Energy (ICE) and mitochondrial dysfunction. The present disclosure also pertains to methods for increasing mental and/or physical performance levels and/or decreasing exertion during exercise in a subject by the administration of C5 ketones.

Abstract: The present application discloses a method for preparing deuterium depleted water, wherein natural water is fed into the device of the present disclosure, and the liquid phase stream continuously flows backwards stage by stage under the combined action of the low-pressure steam compressors and the stream delivery pumps. In a single-stage system, the deuterium is deprived depending on the difference in vapor pressure between 1H2O and 2H2O (and/or 1H2HO), and finally, the deuterium depleted water is produced.

Abstract: The subject invention relates to a process of preparing (R)-3-hydroxybutyric acid or a salt thereof by one-step fermentation with a nonpathogenic microorganism. The fermentation of (R)-3-hydroxybutyric acid was performed by supplying with certain carbon and nitrogen sources. These microorganisms include a Glutamic acid Bacterium HR057 strain or one type of genetically engineered Corynebacterium Glutamicum.

Abstract: The present application discloses a device for multistage continuous preparation of deuterium depleted water, which includes a feeding pump, a plurality of stages of separation systems connected in series, and a receiver, all of which are connected in sequence. Each stage of separation system comprises a distillation column, a vapor-liquid separator, a low-pressure steam compressor, a stream delivery pump, a three-way valve, and a stream output pipe. The present application further discloses a method for preparing deuterium depleted water, wherein natural water is fed into the device of the present disclosure, and the liquid phase stream continuously flows backwards stage by stage under the combined action of the low-pressure steam compressors and the stream delivery pumps. In a single-stage system, the deuterium is deprived depending on the difference in vapor pressure between 1H2O and 2H2O (and/or 1H2HO), and finally, the deuterium depleted water is produced.

Abstract: The present application discloses a device for multistage continuous preparation of deuterium depleted water, which includes a feeding pump, a plurality of stages of separation systems connected in series, and a receiver, all of which are connected in sequence. Each stage of separation system comprises a distillation column, a vapor-liquid separator, a low-pressure steam compressor, a stream delivery pump, a three-way valve, and a stream output pipe. The present application further discloses a method for preparing deuterium depleted water, wherein natural water is fed into the device of the present disclosure, and the liquid phase stream continuously flows backwards stage by stage under the combined action of the low-pressure steam compressors and the stream delivery pumps. In a single-stage system, the deuterium is deprived depending on the difference in vapor pressure between 1H2O and 2H2O (and/or 1H2HO), and finally, the deuterium depleted water is produced.

Abstract: The present disclosure pertains to compositions and methods for the treatment and/or prevention of one or more of obesity, diabetes, metabolic syndrome, Alzheimer's disease, Chronic Fatigue Syndrome (CFS), aging, fibromyalgia, dyslipidemia, hypercholesterolemia, dyslipidemia, Parkinson's disease, migraines, Traumatic Brain Injury (TBI), Attention Deficit Disorder (ADD)/Attention Deficit Hyperactivity Disorder (ADHD), Cancer, Cardiovascular Disease (CVD)/Coronary Artery Disease (CAD), Chronic Pain, neuralgia, depression, amyotrophic lateral sclerosis (ALS), and epilepsy, Insufficient Cellular Energy (ICE) and mitochondrial dysfunction. The present disclosure also pertains to methods for increasing mental and/or physical performance levels and/or decreasing exertion during exercise in a subject by the administration of C5 ketones.

Abstract: The present application discloses a device for multistage continuous preparation of deuterium depleted water, which includes a feeding pump, a plurality of stages of separation systems connected in series, and a receiver, all of which are connected in sequence. Each stage of separation system comprises a distillation column, a vapor-liquid separator, a low-pressure steam compressor, a stream delivery pump, a three-way valve, and a stream output pipe. The present application further discloses a method for preparing deuterium depleted water, wherein natural water is fed into the device of the present disclosure, and the liquid phase stream continuously flows backwards stage by stage under the combined action of the low-pressure steam compressors and the stream delivery pumps. In a single-stage system, the deuterium is deprived depending on the difference in vapor pressure between 1H2O and 2H2O (and/or 1H2HO), and finally, the deuterium depleted water is produced.

Abstract: The subject invention relates to a process of preparing (R)-3-hydroxybutyric acid or a salt thereof by one-step fermentation with a nonpathogenic microorganism. The fermentation of (R)-3-hydroxybutyric acid was performed by supplying with certain carbon and nitrogen sources. These microorganisms include a Glutamic acid Bacterium HR057 strain or one type of genetically engineered Corynebacterium Glutamicum.

Abstract: The subject invention relates to a process of preparing (R)-3-hydroxybutyric acid or a salt thereof by one-step fermentation with a nonpathogenic microorganism. The fermentation of (R)-3-hydroxybutyric acid was performed by supplying with certain carbon and nitrogen sources. These microorganisms include a Glutamic acid Bacterium HR057 strain or one type of genetically engineered Corynebacterium Glutamicum.

Abstract: The subject invention relates to a process of preparing (R)-3-hydroxybutyric acid or a salt thereof by one-step fermentation with a nonpathogenic microorganism. The fermentation of (R)-3-hydroxybutyric acid was performed by supplying with certain carbon and nitrogen sources. These microorganisms include a Glutamic acid Bacterium HR057 strain or one type of genetically engineered Corynebacterium Glutamicum.